Advanced ovarian cancer is difficult to cure. Most patients are free of the disease after completing initial surgery and chemotherapy but the cancer usually comes back. This is because resistance to chemotherapy develops. Scientists are studying the genetic changes that occur in tumours to understand what causes cancer cells to become resistant to drugs. They are also using new imaging technology so they can monitor how tumours are responding to treatment and whether they have spread to other parts of the body.
Understanding drug resistance
Paclitaxel is widely used to treat ovarian cancer but only about half of patients benefit from it due to drug resistance. The mechanisms of resistance are being studied by collecting and analysing tumour samples, both before and after treatment. This information is being used to help develop novel therapeutic approaches to identify whether patients will respond to paclitaxel before they start treatment.
Current open trials in Cambridge
The table below lists current open trials for gynaecological cancer coordinated by the Cambridge Cancer Trials Centre (last updated January 2016).
|Trial name||Trial description||Contact|
|BriTROC1 - Sample collection study in recurrent HGSOC||BriTROC1: Sample collection study to investigate the role of Homologous Recombination Deficiency in platinum sensitivity in recurrent high grade serous ovarian cancer||Dr James Brenton|
|CTCR-OV04 - Molecular Analysis of Response to Treatment in Ovarian Cancer||Molecular Analysis of Response to Treatment in Ovarian Cancer: To investigate the mechanisms of treatment response in ovarian cancer through the study of sequential tissue, ascitic and circulating tumour cells and the establishment of an ex-vivo model.||Dr James Brenton|
|Diffusion weighted Imaging Study in Cancer of the Ovary (DISCOVAR)||Assessing Treatment Response of Peritoneal Metastases in Ovarian Cancer Using Diffusion Weighted Magnetic Resonance Imaging||Dr James Brenton|
|Genetic Biomarkers for Gynaecological Conditions CTCR-OV05||Genetic Biomarkers for Gynaecological Conditions CTCR-OV05|
|GROINSS-V II||GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) II||Dr Peter Baldwin|
|ICON8and ICON8B: Weekly Chemotherapy in Ovarian Cancer||
ICON8: An international phase III randomised trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy, following immediate primary surgery or as part of delayed primary surgery, for women with newly diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer
ICON8B: A phase III randomised trial investigating the combination of dose-fractionated chemotherapy & bevacizumab compared to either strategy alone for the first line treatment of women with newly diagnosed high risk stage III-IV epithelial ovarian, fallopian tube or primary peritoneal cancer
|Dr Helena Earl|
|PiSSARO||p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246||Dr Bristi Basu|
If you would like further information about how to take part in any of the clinical trials listed here that are open to recruitment, please talk to your cancer specialist as patients usually need to be referred by their doctor.
Cambridge Cancer Trials Centre contact for gynaecological cancer trials: Dr Helena Earl